
FDA approves first immunotherapy for advanced rectal cancer
The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly). The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer. Patients with locally advanced… Read More











